{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-027494","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2022-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.536362+00:00","generated_at":"2026-06-24T06:14:17.289344+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ARCA biopharma Q2 net loss narrows to $3.1M; strategic review ongoing","bullets":["Net loss $3.1M ($0.22/sh) vs $4.8M ($0.34/sh) year ago.","Cash and equivalents $46.4M as of June 30, 2022, sufficient through end of 2023.","R&D expenses fell to $1.5M from $3.6M due to completion of rNAPc2 trial enrollment.","Strategic review with advisor Ladenburg Thalmann; exploring acquisition, merger, or other options.","G&A expenses $1.7M, up $0.5M on higher professional fees and consulting costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-027494","json":"https://secwatch.observer/filing/0001564590-22-027494.json","markdown":"https://secwatch.observer/filing/0001564590-22-027494.md","text":"https://secwatch.observer/filing/0001564590-22-027494.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000156459022027494/0001564590-22-027494-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000156459022027494/abio-8k_20220802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T06:14:17.289344+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}